How Will Tirzepatide Change Sleep Apnea Treatment?
Tirzepatide resolved sleep apnea in about 50% of obese patients in the SURMOUNT-OSA trial, but its precise clinical role remains debated.
Quick Facts
What This Study Found
About 50% of obese patients with OSA achieved resolution of their condition with tirzepatide over 52 weeks.
Key Numbers
- Approximately 50% of patients had OSA resolution on tirzepatide
- Treatment period: 52 weeks
- Primary endpoint: change in apnea-hypopnea index (AHI)
How They Did This
Expert forum commentary on the SURMOUNT-OSA randomized controlled trial results.
Why This Research Matters
Sleep apnea affects hundreds of millions worldwide. A drug that can resolve it in half of patients could fundamentally change treatment paradigms.
The Bigger Picture
Tirzepatide represents the first effective pharmacological alternative for OSA management, potentially reducing dependence on CPAP devices.
What This Study Doesn't Tell Us
Expert opinion piece; trial results from a selected population. Long-term outcomes, adherence, and cost-effectiveness unknown.
Questions This Raises
- ?Will insurance cover tirzepatide for sleep apnea?
- ?Can patients stop CPAP once weight loss is achieved?
- ?Will the high cost worsen healthcare disparities?
Trust & Context
- Key Stat:
- ~50% Of obese patients achieved resolution of obstructive sleep apnea with tirzepatide
- Evidence Grade:
- Expert commentary on a randomized controlled trial. Strong trial evidence; expert opinions on clinical role are subjective.
- Study Age:
- Published in 2025.
- Original Title:
- What will the impact be of use of tirzepatide in patients with obstructive sleep apnea (OSA)?
- Published In:
- Sleep, 48(6) (2025)
- Authors:
- Pack, Allan, Grunstein, Ronald, Mokhlesi, Babak, Ryan, Silke, Schwab, Richard, Gozal, David
- Database ID:
- RPEP-12909
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Can tirzepatide cure sleep apnea?
In the SURMOUNT-OSA trial, about 50% of obese patients achieved resolution of sleep apnea after 52 weeks. However, this required sustained treatment.
Will this replace CPAP machines?
Experts say probably not initially, as CPAP provides immediate benefit. Tirzepatide may be used alongside CPAP, with potential to stop CPAP after weight loss.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-12909APA
Pack, Allan; Grunstein, Ronald; Mokhlesi, Babak; Ryan, Silke; Schwab, Richard; Gozal, David. (2025). What will the impact be of use of tirzepatide in patients with obstructive sleep apnea (OSA)?. Sleep, 48(6). https://doi.org/10.1093/sleep/zsaf045
MLA
Pack, Allan, et al. "What will the impact be of use of tirzepatide in patients with obstructive sleep apnea (OSA)?." Sleep, 2025. https://doi.org/10.1093/sleep/zsaf045
RethinkPeptides
RethinkPeptides Research Database. "What will the impact be of use of tirzepatide in patients wi..." RPEP-12909. Retrieved from https://rethinkpeptides.com/research/pack-2025-what-will-the-impact
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.